Principles and Strategies for Designing Best-in-Class Immuno-Oncology ADCs

Deepa Pakianathan, PhD is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities. She currently serves on the boards of Alder Biopharmaceuticals (Nasdaq:ALDR), Calithera Biosciences (Nasdaq: CALA), ForSight:Vision5, Karyopharm Therapeutics (Nasdaq:KPTI) and Oncomed Pharmaceuticals (Nasdaq:OMED).Dr Pakianathan previously served on the boards of Salmedix (acquired by Cephalon), Ilypsa (acquired by Amgen), Proteolix (acquired by Amgen), PTC Therapeutics (Nasdaq:PTCT) and Relypsa(Nasdaq:RYLP). She also led the investments in Cardeas Pharma, KAI Pharmaceuticals (acquired by Amgen), and a PIPE investment in Seattle Genetics (Nasdaq:SGEN).Dr Pakianathan joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice which focuses on drug discovery and development platform technologies that have resulted in multiple novel drugs, including six that are commercially marketed.Prior to joining Delphi, Dr Pakianathan was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies that raised over $9 billion. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997.She serves as Vice-Chair of the San Francisco Conservatory of Music’s Board of Trustees.Dr Pakianathan received her PhD and MS from Wake Forest University and her MSc and BSc from the University of Bombay.